Arcutis Biotherapeutics

ARQT · NASDAQ

$32.82+$0.93 (+2.92%)TodayMarket closed · Oct 20, 7:37 PM ET

Prev close $31.89

Latest news

NewsOct 15, 2:06 PM ETVandana Singh
Why Is Arcutis Biotherapeutics Stock Surging Thursday?
Press releaseSep 4, 7:15 PM ETPRNewswire
Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600
NewsAug 5, 5:06 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
NewsAug 5, 4:00 PM ET
Arcutis Biotherapeutics Q2 EPS $0.11 Beats $0.03 Estimate, Sales $129.861M Beat $118.852M Estimate
Press releaseAug 5, 4:00 PM ETGlobe Newswire
Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
Press releaseJul 15, 8:30 AM ETGlobe Newswire
Attovia Therapeutics Appoints John W. Smither to Board of Directors
NewsMay 6, 5:03 PM ET
Earnings Scheduled For May 6, 2026
Press releaseMay 6, 4:00 PM ETGlobe Newswire
Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
Press releaseApr 8, 9:15 AM ETGlobe Newswire
The Credibility Filter Wall Street Uses to Sort Biotech Winners
Press releaseApr 7, 7:30 AM ETGlobe Newswire
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
NewsMar 3, 8:08 AM ET
Arcutis Biotherapeutics Enrolls The First Participant In Phase 1a/1b Study (ARQ-234-131) To Evaluate Safety And Tolerability For Investigational Arq-234 In Healthy Volunteers And Adults With Moderate To Severe Atopic Dermatitis
Press releaseMar 3, 8:00 AM ETGlobe Newswire
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis
NewsFeb 26, 1:00 PM ET
Forecasting The Future: 4 Analyst Projections For Arcutis Biotherapeutics
NewsFeb 25, 4:07 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
NewsFeb 25, 4:05 PM ET
Arcutis Biotherapeutics Q4 EPS $0.13 Beats $0.10 Estimate, Sales $129.503M Beat $113.055M Estimate
Press releaseFeb 25, 4:00 PM ETGlobe Newswire
Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
NewsFeb 25, 6:11 AM ET
Earnings Scheduled For February 25, 2026
NewsFeb 24, 11:02 AM ET
Preview: Arcutis Biotherapeutics's Earnings
NewsOct 28, 1:06 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
NewsOct 28, 12:18 PM ETAvi Kapoor
Crude Oil Falls Over 2%; PayPal Shares Spike Higher
NewsOct 28, 10:14 AM ETAvi Kapoor
Wayfair, Qorvo, Celestica, United Parcel Service, Regeneron Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Press releaseOct 28, 8:30 AM ETGlobe Newswire
Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results
Press releaseSep 3, 7:30 AM ETGlobe Newswire
Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer
Press releaseJul 31, 7:00 AM ETBusiness Wire
Frazier Life Sciences Closes Oversubscribed $1.3 Billion Venture Fund
NewsJun 6, 11:11 AM ETVandana Singh
Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis
NewsMay 23, 8:01 AM ET
Analyst Expectations For Arcutis Biotherapeutics's Future
NewsApr 3, 8:00 AM ET
Demystifying Arcutis Biotherapeutics: Insights From 9 Analyst Reviews
NewsMar 23, 5:28 PM ETLekha Gupta
Celsius, Lucid And Signet Are Among Top 10 Mid-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?
NewsFeb 26, 7:00 AM ET
A Glimpse Into The Expert Outlook On Arcutis Biotherapeutics Through 5 Analysts
NewsFeb 10, 2:00 PM ET
4 Analysts Have This To Say About Arcutis Biotherapeutics
Press releaseFeb 4, 9:15 AM ETPRNewswire
Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a "Clear Win for Your Skin"
NewsJan 13, 8:01 AM ET
Demystifying Arcutis Biotherapeutics: Insights From 5 Analyst Reviews
NewsOct 22, 7:36 AM ETAvi Kapoor
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4
NewsAug 28, 9:00 AM ET
Assessing Arcutis Biotherapeutics: Insights From 4 Financial Analysts
NewsAug 23, 10:22 AM ETAvi Kapoor
CAVA Group Posts Strong Q2 Results, Joins Bilibili, Workday And Other Big Stocks Moving Higher On Friday
NewsJul 30, 12:00 PM ET
Peeling Back The Layers: Exploring Arcutis Biotherapeutics Through Analyst Insights
NewsJul 10, 8:00 AM ET
Arcutis Biotherapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
NewsJul 8, 8:22 AM ETAvi Kapoor
Intapp, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Why Is Arcutis Biotherapeutics Stock Surging Thursday?

Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

12 Health Care Stocks Moving In Wednesday's After-Market Session

Arcutis Biotherapeutics Q2 EPS $0.11 Beats $0.03 Estimate, Sales $129.861M Beat $118.852M Estimate

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update

Attovia Therapeutics Appoints John W. Smither to Board of Directors

Earnings Scheduled For May 6, 2026

Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update

The Credibility Filter Wall Street Uses to Sort Biotech Winners

Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales

Arcutis Biotherapeutics Enrolls The First Participant In Phase 1a/1b Study (ARQ-234-131) To Evaluate Safety And Tolerability For Investigational Arq-234 In Healthy Volunteers And Adults With Moderate To Severe Atopic Dermatitis

Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis

Forecasting The Future: 4 Analyst Projections For Arcutis Biotherapeutics

12 Health Care Stocks Moving In Wednesday's After-Market Session

Arcutis Biotherapeutics Q4 EPS $0.13 Beats $0.10 Estimate, Sales $129.503M Beat $113.055M Estimate

Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Earnings Scheduled For February 25, 2026

Preview: Arcutis Biotherapeutics's Earnings

12 Health Care Stocks Moving In Tuesday's Intraday Session

Crude Oil Falls Over 2%; PayPal Shares Spike Higher

Wayfair, Qorvo, Celestica, United Parcel Service, Regeneron Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results

Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer

Frazier Life Sciences Closes Oversubscribed $1.3 Billion Venture Fund

Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis

Analyst Expectations For Arcutis Biotherapeutics's Future

Demystifying Arcutis Biotherapeutics: Insights From 9 Analyst Reviews

Celsius, Lucid And Signet Are Among Top 10 Mid-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?

A Glimpse Into The Expert Outlook On Arcutis Biotherapeutics Through 5 Analysts

4 Analysts Have This To Say About Arcutis Biotherapeutics

Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a "Clear Win for Your Skin"

Demystifying Arcutis Biotherapeutics: Insights From 5 Analyst Reviews

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4

Assessing Arcutis Biotherapeutics: Insights From 4 Financial Analysts

CAVA Group Posts Strong Q2 Results, Joins Bilibili, Workday And Other Big Stocks Moving Higher On Friday

Peeling Back The Layers: Exploring Arcutis Biotherapeutics Through Analyst Insights

Arcutis Biotherapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Intapp, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session